Comparison of Duration of Ketoacidosis in Sodium- Glucose Transport-2 Inhibitor (SGLT2i) Users and Non- Users among Individuals with Type 2 Diabetes: Case Series

Khan I, Kovacs B, Mercier S and Thabet P

Department of Critical Care, Montfort Hospital, Canada
University of Ottawa School of Pharmaceutical Sciences, Canada
Institut du Savoir Montfort, Montfort Hospital, Canada
Critical Care Medicine, Montfort Hospital, University of Ottawa, Canada
Department of Internal Medicine, Montfort Hospital, Canada

^*Correspondance to: Imran Khan 

 PDF  Full Text Research Article | Open Access

Abstract:

Background: Sodium Glucose Transport inhibitors (SGLT2i) are approved for the treatment of diabetes but can lead to a complication known as Diabetic Ketoacidosis (DKA). This study aims to compare the duration of ketoacidosis and metabolic profiles between SGLT2i users and non-users with type 2 diabetes. Case Report: A case series was conducted, including patients admitted with DKA between 2016 and 2022. Data were collected from medical records, and statistical analysis was performed using Microsoft Excel. The Montfort Hospital Research Ethics Board (Institute of Savoir Montfort) approved this study (File number: 21-22-02-040). A total of 88 patients were included, with 55 non- SGLT2i users and 33 SGLT2i users. SGLT2i users had significantly prolonged ketoacidosis mean duration compared to non-users (14.45 h vs. 10.93 h, p=0.0001). Conclusion: This retrospective case series of 88 type II diabetes patients admitted with DKA found that SGLT2i users experience significantly longer mean duration of ketoacidosis. Recognizing the risks of prolonged ketoacidosis in critical care settings is crucial, prompting vigilant monitoring and frequent laboratory tests to expedite resolution and improve outcomes. These insights may inform clinical decision-making, potentially reducing ICU stays and improving overall outcomes for individuals with diabetes.

Keywords:

Sodium-glucose transport inhibitors; Diabetic ketoacidosis; Prolonged ketoacidosis; Metabolic profiles; SGLT2i users; Non-SGLT2i users

Cite the Article:

Khan I, Kovacs B, Mercier S, Thabet P. Comparison of Duration of Ketoacidosis in Sodium-Glucose Transport-2 Inhibitor (SGLT2i) Users and Non-Users among Individuals with Type 2 Diabetes: Case Series. Clin Case Rep Int. 2024; 8: 1687.